Expertise in
13
conditions

Markus G. Manz

Zurich, ZH, CH 
Expertise in
13
conditions
Zurich, ZH, CH 

Overview

Markus Manz practices practicing medicine in Zurich, Switzerland.

Mr. Manz is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Langerhans Cell Histiocytosis, Myeloperoxidase Deficiency, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 253 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Zurich, ZH, Switzerland
Other Locations
Bern, BE, Switzerland
Bellinzona, TI, Switzerland
Basel, BS 4056, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Pomalidomide, Dexamethasone
Study Phase: Phase 2
View 1 Less Clinical Trial

253 Total Publications

CD117-targeted HCT preconditioning in AML and MDS.
CD117-targeted HCT preconditioning in AML and MDS.
Journal: Blood
Published: May 28, 2026

Frequently Asked Questions about Markus G. Manz

Is Markus G. Manz a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Markus G. Manz is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Markus G. Manz participate in research or clinical trials?

Yes. Markus G. Manz has published 253 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Markus G. Manz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Manz's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile